The EPO published international patent application EP4159856A1 for novel CRISPR enzymes and systems. The application names multiple research institutions as co-applicants, including the Broad Institute, MIT, Harvard, Rutgers, SKOLTECH, and the US Department of Health and Human Services. Key inventors include Feng Zhang, Konstantin Severinov, Eugene Koonin, and others. The patent covers CRISPR-Cas systems classified under IPC codes C12N 15/10, C12N 9/22, and C12N 15/63. The application designates all major European contracting states.

This is a routine patent publication notice with no immediate compliance obligations for third parties. Entities developing CRISPR-based gene editing technologies should review this publication to assess potential freedom-to-operate implications and identify potential licensing needs. Patent prosecution timelines vary; third parties should monitor the EPO register for subsequent examination results, opposition periods, and granted claims that would create enforceable exclusive rights in designated territories.